References
- O'Dell J. R. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004; 350: 2591–602
- Rollins N., Winick N., Bash R., Booth T. Acute methotrexate neurotoxicity: findings on diffusion‐weighted imaging and correlation with clinical outcome. AJNR Am J Neuroradiol 2004; 25: 1688–95
- Sandoval C., Kutscher M., Jayabose S., Tenner M. Neurotoxicity of intrathecal methotrexate: MR imaging findings. AJNR Am J Neuroradiol 2003; 24: 1887–90
- Szawarski P., Chapman C. S. A woman who couldn't speak: report of methotrexate neurotoxicity. Postgrad Med J 2005; 81: 194–5
- Aplin C. G., Russell‐Jones R. Acute dysarthria induced by low dose methotrexate therapy in a patient with erythrodermic cutaneous T‐cell lymphoma: an unusual manifestation of neurotoxicity. Clin Exp Dermatol 1999; 24: 23–4
- Saravanan V., Kelly C. A. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 143–7
- Grove M. L., Hassell A. B., Hay E. M., Shadforth M. F. Adverse reactions to disease‐modifying anti‐rheumatic drugs in clinical practice. Q J Med 2001; 94: 309–19
- Mahoney D. H Jr., Shuster J. J., Nitschke R., Lauer S. J., Steuber C. P., Winick N., et al. Acute neurotoxicity in children with B‐precursor acute lymphoid leukemia: an association with intermediate‐dose intravenous methotrexate and intrathecal triple therapy – a Pediatric Oncology Group Study. J Clin Oncol 1998; 16: 1712–22
- Lo Nigro L., Di Cataldo A., Schiliro G. Acute neurotoxicity in children with B‐lineage acute lymphoblastic leukemia (B‐ALL) treated with intermediate risk protocols. Med Pediatr Oncol 2000; 35: 449–55
- Morita Y., Fukazawa T., Hirashima M., Kaga K., Kusaoi M., Morita T., et al. The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production. Scand J Rheumatol 2006; 35: 268–72
- Vezmar S., Becker A., Bode U., Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003; 49: 92–104
- Renard D., Westhovens R., Vandenbussche E., Vandenberghe R. Reversible posterior leucoencephalopathy during oral treatment with methotrexate. J Neurol 2004; 251: 226–8
- Kremer J. M., Alarcon G. S., Weinblatt M. E., Kaymakcian M. V., Macaluso M., Cannon G. W., et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate‐associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40: 1829–37
- Searles G., McKendry R. J. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987; 14: 1164–71
- Alarcon G. S., Kremer J. M., Macaluso M., Weinblatt M. E., Cannon G. W., Palmer W. R., et al. Risk factors for methotrexate‐induced lung injury in patients with rheumatoid arthritis. A multicenter, case–control study. Methotrexate‐lung Study Group. Ann Intern Med 1997; 127: 356–64